US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

Cis-regulatory elements (CREs)—including promoters, enhancers, silencers, and insulators—are critical non-coding DNA ...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. The designation ...

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...

This study demonstrates that Setd2 overexpression rescues bivalent gene expression during zygotic genome activation (ZGA) in ...

A deep-learning model trained on human data reveals that promoter mutations may explain a significant portion of unsolved ...

DNA sequences that regulate expression of the insulin gene are located within a region spanning ~400 bp that flank the transcription start site. This region, the insulin promoter, contains a ...

The promoter sequences of gorilla, orangutan, African green monkey, and owl monkey are currently incomplete extending upstream to positions –295, –290, –426, and –510, respectively.

Researchers have developed novel promoters that drive strong and specific gene expression in rod and cone photoreceptors in mid-to-late stages of disease, potentially offering new and improved options ...